Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Smartphone support for stimulant use disorder

Official title: Decentralized Clinical Trial of Contingency Management Digital Therapeutic to Treat Stimulant Use Disorder

Run by DynamiCare Health · NCT07092059 · Data updated 2026-11-12

This program will test whether two different smartphone app services can help adults with stimulant use disorder (cocaine, crack, or meth) reduce use and need for medical care while using the apps at home.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment270 (estimated)
SponsorDynamiCare Health
Industry-sponsored
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedJune 24, 2025
Main results expectedMay 2027
Study endsAugust 2027
Registry record updatedJuly 29, 2025
Trial IDNCT07092059 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) who meet criteria for active or early remission stimulant use disorder, speak/read English, own a smartphone, and can authorize contact with their healthcare providers are the best match for this program.

Probably not a fit

People who are pregnant, need acute detoxification or residential/hospital treatment, are unwilling to allow provider contact or insurance review, or do not have a smartphone are unlikely to benefit from this remote app-based program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, remote study assigns adults with stimulant use disorder to one of two smartphone-based behavioral service packages with a 50/50 chance of each. Participants must be 18 or older, speak and read English, own a smartphone, and agree to let the team contact their healthcare providers and review insurance use; pregnant people and those requiring acute inpatient detox are excluded. The intervention is a digital therapeutic smartphone system delivered entirely remotely by DynamiCare Health, with no medication provided. Investigators will monitor app usage and link to healthcare visit and claims data over time to see whether app users have reduced clinic, emergency department, or hospital visits.

Why it matters

Potential benefit: If successful, the apps could expand access to effective behavioral treatment for stimulant use disorder and help reduce drug use and related healthcare visits.

How similar studies have gone: Behavioral therapies are the most effective treatments for stimulant use disorder and some digital interventions show promise, but delivering these specific services via smartphone is relatively new and evidence is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults who are at least 18 years old, speak/read English, have a smartphone, and who meet criteria for Stimulant Use Disorder, active or early remission. If being discharged to outpatient or intensive outpatient care, the patient is eligible.

Exclusion Criteria:

* Unwilling to authorize communication with any treatment provider(s), requiring acute detoxification from alcohol or opioids or residential or hospital treatment, or other obstacle to longitudinal participation in the study.
* Currently pregnant

Where it's running

  • This is an At-Home Study - no travel or on-site visits are needed at all; Main Office: 6 Liberty Sq, #2102
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.